Company Product Description Indication Status
Phase I
Innovation Pharmaceuticals Inc., of Wakefield, Mass. Brilacidin  Defensin mimetic Inflammatory bowel disease Received agreement from dose-escalation committee to progress dosing to second cohort testing use of delayed-release tablets for colonic delivery in healthy volunteers
Innovation Pharmaceuticals Inc., of Wakefield, Mass. Brilacidin Defensin mimetic Ulcerative colitis Dosed first cohort of healthy volunteers

Notes

For more information about individual companies and/or products, see Cortellis.

No Comments